Edwards outlines ~11.5% 2026 sales growth and $2.97-$3.05 adjusted EPS, supported by TAVR and TMTT momentum (NYSE:EW)
· seekingalpha.com
Edwards Lifesciences Q3 2026 earnings: sales beat, raised guidance, stronger TAVR and TMTT growth.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...